A Phase II Investigator Sponsored Study of Nivolumab in Patients With Advanced Refractory Biliary Tract Cancers
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 27 Nov 2017
At a glance
- Drugs Nivolumab (Primary)
- Indications Biliary cancer; Biliary tract disorders; Gallbladder cancer
- Focus Therapeutic Use
- 21 Nov 2017 Status changed from recruiting to active, no longer recruiting.
- 19 Sep 2016 Status changed from not yet recruiting to recruiting.
- 16 Aug 2016 Planned initiation date changed from 1 Sep 2016 to 1 Nov 2016.